Table 2.
Pilot/phase 1 trials evaluating safety and clinical activity of adoptively transferred autologous ex vivo expanded Vγ9Vδ2 T cells
| Year | Disease | Treatment | n | OR | CR | Reference |
|---|---|---|---|---|---|---|
| 2007 | RCC | Vγ9Vδ2 T cells + zoledronate + IL-2 | 7 | 3/7 | 0/7 | [102] |
| 2008 | RCC | Vγ9Vδ2 T cells + BrHPP + IL-2 | 10 | 0/10 | 0/10 | [103] |
| 2009 | MM | Vγ9Vδ2 T cells + zoledronate + IL-2 | 6 | 0/6 | 0/6 | [104] |
| 2010 | NSCLC | Vγ9Vδ2 T cells + zoledronate + IL-2 | 10 | 0/10 | 0/10 | [105] |
| 2011 | RCC | Vγ9Vδ2 T cells + zoledronate + IL-2 | 11 | 1/11 | 1/11 | [106] |
| 2011 | Melanoma Colon cancer Breast cancer Cervical cancer Ovarian cancer Gastrointestinal cancer |
Vγ9Vδ2 T cells + zoledronate | 18 | 3/12 | 1/12 | [107] |
| 2011 | NSCLC | Vγ9Vδ2 T cells + zoledronate + IL-2 | 15 | 0/12 | 0/12 | [108] |
| 2013 | Colon cancer | Vγ9Vδ2 T cells | 6 | 0/6 | 0/6 | [109] |
| 2014 | NSCLC | Vγ9Vδ2 T cells | 15 | 0/12 | 0/12 | [110] |
| 2014 | Gastric cancer | Vγ9Vδ2 T cells + zoledronate | 7 | [64] |
BrHPP, bromohydrin pyrophosphate; CR, complete response; IL, interleukin; MM, multiple myeloma; NSCLC, non-small cell lung cancer; OR, objective response; RCC, renal cell cancer.